Navigation Links
Techne Corporation Announces That John L. Higgins has Accepted a Seat on Techne's Board
Date:5/19/2009

MINNEAPOLIS, May 19 /PRNewswire-FirstCall/ -- Techne Corporation (Nasdaq: TECH) today announced that Mr. John L. Higgins has accepted a position on Techne's Board of Directors and will also serve as a member of Techne's Audit, Compensation and Nominations and Governance Committees. Mr. Higgins' initial term will begin immediately and run through October 29, 2009. Techne's shareholders reelect Directors on an annual basis.

Mr. Higgins has been President and Chief Executive Officer of Ligand Pharmaceuticals Incorporated since January 2007 and has been a member of Ligand's Board of Directors since March 2007. From 1997 until joining Ligand, Mr. Higgins was with Connetics Corporation, a specialty pharmaceutical company, as its Chief Financial Officer, and also served as Executive Vice President, Finance and Administration and Corporate Development at Connetics from January 2002 until its acquisition by Stiefel Laboratories, Inc. in December 2006.

Mr. Higgins was previously a member of the executive management team at BioCryst Pharmaceuticals, Inc., a biopharmaceutical company. Currently, he is a Director of BioCryst and serves as Chairperson of its Audit Committee. Before joining BioCryst in 1994, Mr. Higgins was a member of the healthcare banking team of Dillon, Read & Co. Inc., an investment banking firm. Mr. Higgins also serves as Chairman of CoMentis, Inc, a biopharmaceutical company, and has served as a director of numerous public and private companies. He graduated Magna Cum Laude with an A.B. from Colgate University.

Mr. Thomas E. Oland, Techne's Chairman and CEO, said, "I am extremely pleased with Mr. Higgins' decision to accept a position on Techne's Board. His combination of biopharmaceutical business experience and background as a chief financial officer and investment banker, combined with his current responsibilities as a CEO, are all essential qualifications that will benefit Techne. We are very fortunate to have a person of his caliber on our Board. I am very confident that he will make a significant contribution to our future success."

Techne Corporation has two operating subsidiaries: Research and Diagnostic Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems Europe, Ltd. (R&D Europe) of Abingdon, England. R&D Systems is a specialty manufacturer of biological products. R&D Systems has two subsidiaries, BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D Systems China Co. Ltd., (R&D China), located in Shanghai, China. BiosPacific is a worldwide supplier of biologics to manufacturers of in vitro diagnostic systems and immunodiagnostic kits. R&D China and R&D Europe distribute biotechnology products.


'/>"/>
SOURCE Techne Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. Techne Corporation Releases Unaudited Third Quarter Results for Fiscal Year 2009
2. Techne Corporation Declares Dividend and Announces an Increase in Its Share Repurchase Program
3. Techne Corporation Declares Dividend
4. Techne Corporation Releases Unaudited First Quarter Results for Fiscal Year 2009
5. Techne Corporation Releases Unaudited Fourth Quarter Results for Fiscal Year 2008
6. Techne Corporation Releases Unaudited Second Quarter Results for Fiscal Year 2008
7. Techne Corporation Announces Share Repurchase Authorization
8. Onyx Pharmaceuticals Files Complaint Against Bayer Corporation
9. Odyssey Thera Announces Collaboration With Mitsubishi Tanabe Pharma Corporation, and Issuance of Core Patent in Japan
10. Dendreon Corporation CEO Mitchell H. Gold, M.D. Named Ernst & Young Entrepreneur of the Year(R) 2009 Award Finalist in the Pacific Northwest
11. Apex Bioventures Acquisition Corporation Receives Notice of Extension from NYSE Amex
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... ... June 24, 2016 , ... Researchers at the Universita Politecnica delle ... people with peritoneal or pleural mesothelioma. Their findings are the subject of a new ... , Diagnostic biomarkers are signposts in the blood, lung fluid or tissue of mesothelioma ...
(Date:6/23/2016)... June 23, 2016 /PRNewswire/ - FACIT has announced ... biotechnology company, Propellon Therapeutics Inc. ("Propellon" ... commercialization of a portfolio of first-in-class WDR5 inhibitors ... such as WDR5 represent an exciting class of ... precision medicine for cancer patients. Substantial advances have ...
(Date:6/23/2016)... -- The Prostate Cancer Foundation (PCF) is pleased to announce 24 new ... prostate cancer. Members of the Class of 2016 were selected from a pool ... Read More About the Class of 2016 PCF Young Investigators ... ... ...
(Date:6/23/2016)... OTTAWA, ON (PRWEB) , ... June 23, 2016 , ... ... former DNA Technical Leader at the Arkansas State Crime Laboratory, has joined STACS DNA ... joining the STACS DNA team,” said Jocelyn Tremblay, President and COO of STACS DNA. ...
Breaking Biology Technology:
(Date:6/15/2016)... , June 15, 2016 ... report titled "Gesture Recognition Market by Application Market - Global Industry ... - 2024". According to the report, the  global gesture ... in 2015 and is estimated to grow at ... billion by 2024.  Increasing application of ...
(Date:6/2/2016)... , June 2, 2016 The Department ... has awarded the 44 million US Dollar project, for the ... Vehicle Plates including Personalization, Enrolment, and IT Infrastructure , ... in the production and implementation of Identity Management Solutions. Numerous ... however Decatur was selected for the ...
(Date:5/20/2016)... 20, 2016  VoiceIt is excited to announce ... By working together, VoiceIt and VoicePass ... and VoicePass take slightly different approaches to voice ... security and usability. ... new partnership. "This marketing and technology ...
Breaking Biology News(10 mins):